化合物SUDOTERBFREEBASE | 676266-31-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 化合物SUDOTERBFREEBASE
• 英文名称: N-{2-methyl-5-phenyl-3-[4-(3-trifluoromethyl-phenyl)-piperazin-1-ylmethyl]-pyrrol-1-yl}-isonicotinamide
• 英文别名: N-(3-{[4-(3-trifluoromethylphenyl)piperazinyl]methyl}-2-methyl-5-phenylpyrrolyl)-4-pyridylcarboxamide；Sudoterb；N-[2-methyl-5-phenyl-3-[[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]methyl]pyrrol-1-yl]pyridine-4-carboxamide
• CAS: 676266-31-2
• 化学式: C₂₉H₂₈F₃N₅O
• 分子量: 519.569
• InChiKey: PRXZOPNJRFEGRH-UHFFFAOYSA-N

物化性质

• 密度：
  1.27±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  38
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  53.4
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  化合物SUDOTERBFREEBASE 在 盐酸 作用下， 以 乙酸乙酯 为溶剂， 反应 2.0h， 以99%的产率得到N-{2-methyl-5-phenyl-3-[4-(3-trifluoromethyl-phenyl)-piperazin-1-ylmethyl]-pyrrol-1-yl}-isonicotinamide dihydrochloride
  参考文献：
  名称：

  WO2006/109323

  摘要：

  公开号：
• 作为产物：
  描述：

  N-(5-甲基-2-苯基吡咯基)-4 吡啶羧酰胺 、 1-(3-三氟甲基苯基)哌嗪单盐酸盐 在 1-(3-三氟甲基苯基)哌嗪单盐酸盐 作用下， 以24.34的产率得到化合物SUDOTERBFREEBASE
  参考文献：
  名称：

  Antimycobacterial pharmaceutical composition

  摘要：

  本文描述了一种用于治疗结核病的抗分枝杆菌组合和组成物。使用的化合物为式(I)的N-(3-[[4-(3-三氟甲基苯基)哌嗪基]甲基]-2-甲基-5-苯基吡咯烷基)-4-吡啶基甲酰胺或其药学上可接受的非毒性盐，以及一种或多种一线抗结核药物。

  公开号：

  US20050256128A1

文献信息

• [EN] PYRROLE DERIVATIVES AS ANTIMYCOBACTERIAL COMPOUNDS<br/>[FR] DERIVES DE PYRROLE SERVANT DE COMPOSES ANTI-MYCOBACTERIENS
  申请人：LUPIN LTD

  公开号：WO2004026828A1

  公开（公告）日：2004-04-01

  Novel pyrrole derivatives of formula (I), and their pharmaceutically acceptable acid addition salts having superior antimycobacterial activity against clinically sensitive as well as resistant strains of Mycobacterium tuberculosis as well as having lesser toxicity compared to known compounds. The use of the novel compounds of formula (I) for treatment of latent tuberculosis including Multi Drug Resistant Tuberculosis (MDR TB). The methods for preparation of the novel compounds, pharmaceutical compositions containing the novel compounds and method of treating MDR TB by administration of compounds of formula (I).

  公式(I)的新型吡咯衍生物及其药学上可接受的酸盐，在临床上对结核分枝杆菌的敏感和耐药菌株具有优越的抗结核活性，且与已知化合物相比具有较低的毒性。利用公式(I)的新型化合物治疗潜伏性结核病，包括多药耐药结核病（MDR TB）。制备新型化合物的方法，含有新型化合物的药物组合物以及通过给予公式(I)化合物治疗MDR TB的方法。
• PREPARATION OF [2-METHYL-5-PHENYL-3-(PIPERAZIN-1-YLMETHYL)] PYRROLE DERIVATIVES
  申请人：Arora Sudershan Kumar

  公开号：US20090118509A1

  公开（公告）日：2009-05-07

  A process for the preparation of compounds of Formula I and their pharmaceutically acceptable acid addition salt wherein, R 1 is phenyl or substituted phenyl R 2 is selected from a group consisting of phenyl which is unsubstituted or substituted with 1 or 2 substituents, each independently selected from Cl, F, or pyridine, or naphthalene, or NHCOR 4 wherein R 4 is aryl, unsubstituted or substituted heteroaryl, unsubstituted or substituted heterocyclyl. R 3 is selected from a group of formula wherein R 5 is phenyl which is unsubstituted or substituted with 1 or 2 substituents each independently selected from the group consisting of halogen, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, nitro, amino, haloalkyl, haloalkoxy etc.; unsubstituted or substituted benzyl; unsubstituted or substituted heteroaryl; unsubstituted or substituted heteroaroyl; unsubstituted or substituted diphenylmethyl, n=0-2 and X═—NCH 3 , CH 2 , S, SO, or SO 2 Such that when R 2 is phenyl, which is unsubstituted or substituted with 1 or 2 substituents, each independently selected from Cl, F; R 5 is not C 1 -C 4 alkyl, or X is not —NCH 3 , CH 2 , S, SO, or SO 2 , when n=1, or X is not —CH 2 when n=0; comprising the steps of (a) reacting compound of Formula II with a chlorinating agent in the presence or absence of catalytic amount of N,N-dimethylformamide to yield the compound of Formula III, (b) reacting the compound of Formula III with a compound of Formula R 1 H (R 1 is as defined above), in presence of a Lewis acid to obtain the compound of Formula IV, (c) reacting the compound of Formula IV with a compound of Formula R 2 NH 2 (R 2 is as defined above) in presence of catalytic amounts of an aryl or alkyl sulphonic acid in an organic solvent to obtain the compound of Formula V, (d) reacting the compound of Formula V with various secondary amines of the Formula R 3 H (R 3 is as defined above) in the presence of formaldehyde and acetic acid in acetonitrile followed by crystallization yield the compound of Formula I, (e) purifying the compound of Formula I by crystallization, (f) converting the purified compound of Formula I to a pharmaceutically acceptable acid addition salt.

  一种制备I式化合物及其药学上可接受的酸加成盐的方法，其中， R1是苯基或取代苯基； R2选自以下组：未取代或取代有1或2个取代基的苯基，每个独立地选自Cl，F，或吡啶；或萘基；或NHCOR4，其中R4是芳基，未取代或取代杂芳基，未取代或取代杂环基； R3选自以下式的组： 其中R5是未取代或取代有1或2个取代基的苯基，每个独立地选自卤素，C1-C4烷基，C1-C4烷氧基，硝基，氨基，卤代烷基，卤代烷氧基等；未取代或取代苄基；未取代或取代杂芳基；未取代或取代杂芳酰基；未取代或取代二苯甲基，n=0-2，X═—NCH3，CH2，S，SO或SO2； 当R2为未取代或取代有1或2个取代基的苯基，每个独立地选自Cl，F时；当R5不是C1-C4烷基，或当n=1时，X不是—NCH3， ，S，SO或SO2，当n=0时，X不是— ； 包括以下步骤： (a)在N，N-二甲基甲酰胺的存在或缺席下，将II式化合物与氯化剂反应，得到III式化合物； (b)在Lewis酸存在下，将III式化合物与R1H式化合物（其中R1如上定义）反应，得到IV式化合物； (c)在有机溶剂中，在芳基或烷基磺酸催化下，将IV式化合物与R2NH2式化合物（其中R2如上定义）反应，得到V式化合物； (d)在乙腈中，在甲醛和乙酸的存在下，将V式化合物与R3H式的各种二级胺（其中R3如上定义）反应，然后结晶，得到I式化合物； (e)通过结晶纯化I式化合物； (f)将纯化后的I式化合物转化为药学上可接受的酸加成盐。
• IMIDAZO [1,2-a]PYRIDINE COMPOUNDS, SYNTHESIS THEREOF, AND METHODS OF USING SAME
  申请人：Miller Marvin J.

  公开号：US20120220457A1

  公开（公告）日：2012-08-30

  Embodiments relate to the field of chemistry and biochemistry, and, more specifically, to imidazopyridine compounds, synthesis thereof, and methods of using same. Disclosed herein are various imidazo[1,2-a]pyhdine compounds and methods of using the novel compounds to treat or prevent tuberculosis in a subject or to inhibit fungal growth on plant species. Other embodiments include methods of synthesizing imidazo [1,2- a]pyridine compounds, such as the disclosed imidazo[1,2-a]pyridine compounds.

  本实施例涉及化学和生物化学领域，更具体地涉及咪唑吡啶化合物，其合成以及使用方法。本文公开了各种咪唑[1,2-a]吡啶化合物，以及使用这些新型化合物治疗或预防主体的结核病或抑制植物物种上的真菌生长的方法。其他实施例包括合成咪唑[1,2-a]吡啶化合物的方法，例如公开的咪唑[1,2-a]吡啶化合物。
• IMIDAZO[1,2-A]PYRIDINE COMPOUNDS, SYNTHESIS THEREOF, AND METHODS OF USING SAME
  申请人：University of Notre Dame du Lac

  公开号：EP3257854A1

  公开（公告）日：2017-12-20

  Embodiments relate to the field of chemistry and biochemistry, and, more specifically, to imidazopyridine compounds, synthesis thereof, and methods of using same. Disclosed herein are various imidazo[1,2-a]pyridine compounds and methods of using the novel compounds to treat or prevent tuberculosis in a subject or to inhibit fungal growth on plant species. Other embodiments include methods of synthesizing imidazo[1,2-a]pyridine compounds, such as the disclosed imidazo[1,2-a]pyridine compounds.

  本发明实施例涉及化学和生物化学领域，更具体地说，涉及咪唑并吡啶化合物、其合成及其使用方法。本发明公开了各种咪唑并[1,2-a]吡啶化合物以及使用这些新型化合物治疗或预防受试者的结核病或抑制植物真菌生长的方法。其他实施方案包括合成咪唑并[1,2-a]吡啶化合物的方法，例如所公开的咪唑并[1,2-a]吡啶化合物。
• Imidazo [1,2-a]pyridine compounds, synthesis thereof, and methods of using same
  申请人：UNIVERSITY OF NOTRE DAME DU LAC

  公开号：US10913737B2

  公开（公告）日：2021-02-09

  Embodiments relate to the field of chemistry and biochemistry, and, more specifically, to imidazopyridine compounds, synthesis thereof, and methods of using same. Disclosed herein are various imidazo[1,2-a]pyhdine compounds and methods of using the novel compounds to treat or prevent tuberculosis in a subject or to inhibit fungal growth on plant species. Other embodiments include methods of synthesizing imidazo[1,2-a]pyridine compounds, such as the disclosed imidazo[1,2-a]pyridine compounds.

  本发明实施例涉及化学和生物化学领域，更具体地说，涉及咪唑并吡啶化合物、其合成及其使用方法。本文公开了各种咪唑并[1,2-a]吡啶化合物以及使用这些新型化合物治疗或预防受试者的结核病或抑制植物上真菌生长的方法。其他实施方案包括合成咪唑并[1,2-a]吡啶化合物的方法，例如所公开的咪唑并[1,2-a]吡啶化合物。